Evan Wang
Stock Analyst at Guggenheim
(0.16)
# 3,704
Out of 4,667 analysts
6
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVAC CureVac | Reiterates: Neutral | n/a | $2.56 | - | 1 | Apr 5, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $0.74 | +1,113.43% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $4.56 | +272.81% | 1 | Mar 22, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.48 | - | 2 | Mar 14, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $38.08 | - | 1 | Apr 26, 2023 |
CureVac
Apr 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $2.56
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $0.74
Upside: +1,113.43%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $4.56
Upside: +272.81%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.48
Upside: -
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $38.08
Upside: -